Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Envafolimab with Short-course Radiation and CAPEOX for Rectal Cancer
NCT05858567Phase 2Unknown
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of envafolimab in rectal adenocarcinoma, sponsored by Sir Run-Run Shaw Hospital. Status: unknown.
02
Drugs
envafolimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05858567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858567.